Institut Necker Enfants Malades

What Institut Necker Enfants Malades does

Institut Necker Enfants Malades (INEM) is a public biomedical research institute founded in 2014 and located on the Hôpital Necker-Enfants Malades campus in Paris, France, operating under the triple institutional tutelage of INSERM, CNRS, and Université Paris Cité. It brings together more than 300 researchers and staff from over 40 countries, organized into 20 research teams working across six strategic axes: immunity, inflammation and infection; cell plasticity and regeneration; metabolism; epigenetics and gene regulation; organelle dynamics and cell signaling; and stem cells and organoids. The institute focuses on fundamental and translational research spanning cell biology, molecular biology, genetics, immunology, metabolism, and host-pathogen interactions, with particular emphasis on pediatric diseases, rare diseases, metabolic disorders, autoimmune conditions, infectious diseases, and cancer. Co-location with Hôpital Necker-Enfants Malades (AP-HP) enables seamless integration of laboratory discoveries with clinical translation, exemplified by the European approval of alpelisib for PROS syndromes derived from in-house translational research.

INEM's technology stack is centered on advanced wet-lab methodologies rather than commercial products, including organoid cultures, CRISPR gene editing and screening (including CRISPRi/a), single-cell multi-omics combining genomics, transcriptomics, and proteomics, high-resolution microscopy and spatial transcriptomics, microfabrication and mechanobiology platforms, molecular biosensors, gnotobiotic and zebrafish animal models, and in vitro systems for studying fastidious bacteria. The institute operates shared core facilities in animal husbandry, histology, flow cytometry, imaging, genomics, bioinformatics, proteomics, viral production, and metabolomics. Research outputs include six patents filed through the PUI UPCité ValoCité maturation program around NF-kB/RelB biomarkers and therapeutic targets.

INEM is a public research institution and does not sell commercial products or services. Its operating model relies on core institutional funding from INSERM, CNRS, and Université Paris Cité, supplemented by competitive research grants from French national agencies (ANR, ARC, FRM, Institut National du Cancer) and European/international sources (European Research Council, Horizon Europe, European Union Framework Programs, Gates Foundation, European Diabetes Foundation, SFGG/Fondation de France). The institute's "customers" are researchers, physicians, students, and the broader public engaged through academic collaborations, clinical translation, training programs, and science communication events. It maintains extensive international collaborations with leading institutions including Institut Pasteur, Institut Imagine, University of Chicago, Rockefeller University, Karolinska Institutet, Weizmann Institute, the Francis Crick Institute, ETH Zurich, and others.

Name

Institut Necker Enfants Malades

Legal name

Institut Necker Enfants Malades

Website

https://institut-necker-enfants-malades.fr

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

INEM is a public biomedical research institute in Paris, France, operating under the joint oversight of INSERM, CNRS, and Université Paris Cité. It conducts fundamental and translational research across metabolism, immunology, host-pathogen interactions, and cell biology, serving academic researchers, clinicians, and students through 20 teams co-located with Hôpital Necker-Enfants Malades.

Ownership category

akta.pro rank

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Public Institutional Funding: Core funding from INSERM, CNRS, and Université Paris Cité as a public research institute under triple institutional tutelage
2. Competitive Research Grants: Funding from national agencies (ANR, ARC, FRM, Institut National du Cancer) and European sources (European Research Council grants, Horizon Europe, European Union Framework Programs)
3. International Funding: Funding from international sources including European Research Council (15 ERC grants mentioned), Gates Foundation, European Diabetes Foundation, SFGG/Fondation de France
4. European Consortia: Horizon Europe project funding through multi-partner European consortia such as ARTiDE (8 partners), NicheAdapt, ChronoBridge, and others

Go-to-market motion1 record

Distribution channels1 record

Marketing channels9 records

Core offering

Institut Necker Enfants Malades (INEM) is a public biomedical research institute that conducts fundamental and translational research across cell biology, molecular biology, genetics, immunology, metabolism, and host-pathogen interactions. It delivers research output through 20 research teams organized around six strategic axes, supported by state-of-the-art core facilities (Techno-Hub) covering animal house, histology, flow cytometry, imaging, genomics, bioinformatics, proteomics, viral production, and metabolomics. The institute bridges basic discovery science with clinical translation in pediatric diseases, rare diseases, metabolic disorders, autoimmune diseases, infectious diseases, and cancer, co-located with Hôpital Necker-Enfants Malades.

Product overview

Institut Necker Enfants Malades (INEM) is a biomedical research institute created in 2014, located on the Necker-Enfants Malades Hospital campus in Paris. Under the triple tutelage of INSERM, CNRS, and Université Paris Cité, INEM brings together over 300 researchers across 20 research teams organized around six strategic axes: immunity, inflammation and infection; cell plasticity and regeneration; metabolism; epigenetics and gene regulation; organelle dynamics and cell signaling; and stem cells and organoids. The institute conducts fundamental and translational research spanning from basic discoveries to therapeutic innovation, with key contributions in transplantation, biotherapy, and gene therapy. Research is supported by state-of-the-art core facilities including animal house, histology, flow cytometry, imaging, genomics, bioinformatics, proteomics, viral production, and metabolomics platforms. INEM is not a product company; it is a public research institution focused on advancing understanding of human diseases through basic and translational biomedical research.

Differentiator

Problem solved

Functional benefit

Products and services

• Médecine Translationnelle et Thérapies Ciblées Research Program Translational research program developing targeted therapies for rare diseases, led by Guillaume Canaud. Includes the EPIK-P3 clinical trial that led to European approval of alpelisib for PIK3CA-Related Overgrowth Spectrum (PROS) syndromes. For patients with rare overgrowth disorders and the clinical research community.
• StemNest Lab Research Program Research program studying mechanical regulation of intestinal stem cell niche, led by Meryem Baghdadi (ERC Starting Grant 2025). For the scientific research community studying tissue development and intestinal stem cell biology.
• Immunity in Health and Disease Research Program Immunology research program investigating roles of B and T cells in autoimmune and infectious diseases, with focus on identifying novel pro-inflammatory and anti-inflammatory T cell, B cell, and plasma cell subsets. Led by Simon Fillatreau and coordinates the European ARTiDE consortium (8 partners). For the immunology research community and clinical researchers.
• Host-Microbiota Interaction Research Program Microbiota research program studying gut microbiota interactions with the host immune system, focusing on Segmented Filamentous Bacteria (SFB). Led by Pamela Schnupf with collaborations including Institut Pasteur, Institut Imagine, and the GEMS Consortium. For the microbiome research community and infectious disease researchers.
• Host-Pathogen Interactions Research Program Research program on integrative biology of host-pathogen interactions, focusing on Neisseria meningitidis and Staphylococcus aureus pathogenesis. Co-led by Mathieu Coureuil and Anne Jamet with collaborations including Institut Cochin and CIMI Paris. For the infectious disease research community.
• Cell Growth Control by Nutrients Research Program Research program on nutrient-dependent cell growth regulation, mTOR pathway, and cellular size control. Led by Mario Pende with Véronique Baud's group contributing on NF-kB, Metabolism, Immunity and Cancer. For the cancer and metabolism research communities.
• IMMEDIAB Research Program Research program on immune-metabolic interactions in diabetes, led by Nicolas Venteclef. Awarded the Fondation pour la Recherche Médicale Label in 2025. For the diabetes and immunometabolism research communities.
• AI2B Research Program Research program on autoimmunity against type I interferons and B cell biology (Autoimmunité et immunité lymphocytaire B). Co-led by Matthieu Mahévas (Professeur) and Pascal Chappert. For the autoimmunity and B cell immunology research communities.
• Epigenetics and Development Research Program Research program on epigenetics and development, focusing on transcription factors and genetic networks in kidney disease. Led by Marco Pontoglio with close collaboration with Fabiola Terzi's team. For the epigenetics and kidney disease research communities.
• Protein Misfolding in Respiratory Epithelial Diseases Research Program Research program on cystic fibrosis treatment, exploring misfolded protein biogenesis and correction using CFTR protein as a model system. Led by Professeure Isabelle Sermet-Gaudelus. For the cystic fibrosis and protein biology research communities.
• PRL/GH Pathophysiology: Translational Approaches Research Program Research program studying prolactin and growth hormone pathophysiology, with focus on prostate cancer research. Led by Vincent Goffin. For the endocrinology and prostate cancer research communities.
• INEM Techno-Hub Core Facilities State-of-the-art core facilities and shared technological platforms serving INEM researchers and collaborators. Includes animal house with zebrafish, histology, flow cytometry, imaging (high-resolution microscopy, confocal, CLEM-SEM, spatial transcriptomics), genomics, bioinformatics, proteomics, viral production, and metabolomics platforms. For academic researchers and principal investigators at INEM and partner institutions.

Quantifiable outcome

• 15 ERC grants obtained by Principal Investigators
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

40 partnerships are on record, tiered minor and core.

• SanofiminorStrategic or Co-development Partner · 1 July 2023Industry collaboration mentioned in Oumaima Baaziz's Pint of Science talk on 3D cancer immunotherapy research between Leukomotion Lab and Sanofi.
• Institut ImaginecoreStrategic or Co-development PartnerSister institute on the Necker campus, one of two major research institutes. Federative research structure offering shared access to cutting-edge technological platforms and advanced equipment. Collaborative research especially in immunology and genetics.
• Institut PasteurcoreStrategic or Co-development PartnerMajor research partner collaborating on host-pathogen interactions, microbiota studies, immunology, and autophagy research. Shared access to core facilities and equipment.
• Hôpital Necker-Enfants Malades (AP-HP)coreStrategic or Co-development PartnerClinical partner providing patient cohorts, clinical trial infrastructure, and translational research opportunities. Campus co-location enables seamless basic-to-clinical translation.
• Institut CochinminorStrategic or Co-development PartnerCollaborative research partner in host-pathogen biology studies, particularly in meningococcal disease research with Coureuil/Jamet team.
• CIMI ParisminorStrategic or Co-development PartnerCollaborative partner in host-pathogen research including meningococcal studies.
• Institut des Saints-PèresminorStrategic or Co-development PartnerResearch collaboration in host-pathogen interaction studies.
• PICMOminorStrategic or Co-development PartnerCollaborative research partner in host-pathogen interaction studies.
• University of ChicagominorStrategic or Co-development PartnerInternational collaboration with Bana Jabri as keynote speaker at 10-year anniversary symposium.
• The Rockefeller UniversityminorStrategic or Co-development PartnerInternational collaboration with Kivanc Birsoy as keynote speaker at 10-year anniversary symposium.
• Institut PasteurminorStrategic or Co-development PartnerInternational collaboration with Yasmine Belkaid as keynote speaker at 10-year anniversary symposium.
• Weizmann Institute of ScienceminorStrategic or Co-development PartnerInternational research collaboration with Eran Segal presenting at 10-year anniversary symposium.
• The Francis Crick InstituteminorStrategic or Co-development PartnerInternational collaboration with Karen Vousden presenting at 10-year anniversary symposium.
• University of MarylandminorStrategic or Co-development PartnerInternational collaboration in Schnupf lab's microbiota research with GEMS consortium investigators.
• Université Catholique de LouvainminorStrategic or Co-development PartnerInternational collaboration with Nathalie Delzenne presenting at 10-year anniversary symposium.
• University of CambridgeminorStrategic or Co-development PartnerInternational collaboration with Clémence Blouet presenting at 10-year anniversary symposium.
• Karolinska InstitutetminorStrategic or Co-development PartnerInternational collaboration with Mikael Rydén presenting at 10-year anniversary symposium.
• ETH ZurichminorStrategic or Co-development PartnerInternational collaboration with Christian Wolfrum presenting at 10-year anniversary symposium.
• Leibniz FMPminorStrategic or Co-development PartnerInternational collaboration with Volker Haucke presenting at 10-year anniversary symposium.
• Lille Neuroscience & CognitionminorStrategic or Co-development PartnerFrench research collaboration with Paolo Giacobini presenting at 10-year anniversary symposium.
• Spanish National Center for Cardiovascular ResearchminorStrategic or Co-development PartnerInternational collaboration with David Sancho presenting at 10-year anniversary symposium.
• Institut Gustave RoussyminorStrategic or Co-development PartnerFrench research collaboration with Florent Ginhoux presenting at 10-year anniversary symposium.
• INSERM U1151 / CNRS UMR 8253coreStrategic or Co-development PartnerCore institutional partners providing public research funding and institutional support as part of the triple tutelle arrangement.
• Université Paris CitécoreStrategic or Co-development PartnerCore institutional partner providing public research funding and institutional support as part of the triple tutelle arrangement.
• IBENS (Institut de Biologie de l'École Normale Supérieure)minorStrategic or Co-development PartnerCollaboration with Nathalie Spassky's lab in ependymal cell differentiation research with Pende team.
• Institut ImagineminorStrategic or Co-development PartnerCollaboration with Jean-Laurent Casanova in AI2B team's Cell publication on interferon autoimmunity.
• Institut PasteurminorStrategic or Co-development PartnerCollaboration with Félix Rey in AI2B team's Cell publication on interferon autoimmunity.
• CIMI ParisminorStrategic or Co-development PartnerCollaboration with Guy Gorochov in AI2B team's Cell publication on interferon autoimmunity.
• Institut PasteurminorStrategic or Co-development PartnerCollaboration in Schnupf lab's Nature Communications publication on segmented filamentous bacteria.
• Institut ImagineminorStrategic or Co-development PartnerCollaboration in Schnupf lab's Nature Communications publication on segmented filamentous bacteria.
• GEMS ConsortiumminorStrategic or Co-development PartnerGlobal Enteric Multicenter Study collaboration in Schnupf lab's SFB research.
• Horizon Europe ARTiDE Consortium (8 partners)coreStrategic or Co-development PartnerEuropean consortium of 8 academic and industrial partners coordinated by Simon Fillatreau for developing TCR-engineered Tregs for type 1 diabetes cell therapy. Includes clinical trial development with AP-HP.
• Paris Research EcosystemcoreStrategic or Co-development PartnerBroader Paris research ecosystem including collaborations within Necker campus, Institut Pasteur, Université Paris Cité, and broader Paris research community.
• University of Montreal / Montreal Diabetes Research CenterminorStrategic or Co-development PartnerInternational collaboration with Marc Prentki as seminar speaker, expert in diabetes and beta-cell function research.
• University of PadovaminorStrategic or Co-development PartnerInternational collaboration with Sirio Dupont as seminar speaker, expert in mitochondrial mechanotransduction.
• SickKids TorontominorStrategic or Co-development PartnerInternational research collaboration where Meryem Baghdadi conducted postdoc research on intestinal stem cells before establishing StemNest lab at INEM.
• Stanford UniversityminorStrategic or Co-development PartnerHistoric collaboration - Laurent Reber conducted postdoc in Steve Galli's lab studying mast cell biology and allergic diseases.
• Institut CurieminorStrategic or Co-development PartnerMeryem Baghdadi conducted research at Institut Curie before joining INEM, exploring mechanical niche regulation in intestinal stem cells.
• CFATG (Club Francophone de L'AuToPhaGie)minorStrategic or Co-development PartnerFrench association of scientists promoting autophagy research. INEM researchers (Aurore Claude-Taupin, Etienne Morel) co-organizing 13th CFATG Scientific Days on Autophagy.
• SBCF (Société de Biologie Cellulaire de France)minorStrategic or Co-development PartnerFrench cell biology society. INEM researcher (Etienne Morel) co-organizing Cell Biology of Eukaryogenesis 2026 congress.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Institut Cochin: Paris-based INSERM/CNRS/Université Paris Cité research institute with overlapping scope in immunology, host-pathogen biology, and biomedical research. Direct partner in INEM's Coureuil/Jamet team meningococcal research.
• Institut Imagine: Sister institute co-located on the Necker campus, focused on genetic diseases and pediatric research. Shares infrastructure, joint clinical appointments, and collaborative projects with INEM, making it the most geographically and operationally comparable peer.
• Institut Pasteur: Paris-based biomedical research institute with overlapping scope in immunology, host-pathogen interactions, and microbiota research. Active collaboration partner with INEM and the most directly comparable French research institute for both scientific mission and operational scale.
• Francis Crick Institute: London-based biomedical discovery research institute with comparable ~1,500+ researcher scale, multi-axis research organization, and translational focus. Comparable in mission (fundamental biomedical research) and in pursuing ERC and international grant funding.
• Helmholtz Centre for Infection Research (HZI): German research center with strong focus on infectious disease and immunology research. Comparable in operating model (public research institute), translational focus, and core facility infrastructure.
• The Rockefeller University: New York-based biomedical research university with comparable scale (~300 labs), focus on fundamental biomedical discovery, and history of translational breakthroughs. Listed as international symposium partner for INEM's 10-year anniversary.
• Max Planck Institute for Molecular Genetics: Berlin-based biomedical research institute with comparable focus on molecular biology, genetics, and developmental biology. Operates under similar public-research funding model with strong EU grant capture.
• Karolinska Institutet: Swedish medical university with strong biomedical research, pediatric and translational focus, and close integration with Karolinska University Hospital. Comparable in translational research model and European grant capture.
• Institut de Recherche Saint-Louis (IRSL) / INSERM UMR_S 1160: Paris-based biomedical research institute under INSERM/Université Paris Cité with overlapping translational research focus. Comparable in funding model, host institution, and research mission.

Broad incumbents

• Broad Institute of MIT and Harvard: Large-scale US genomics and biomedical research institute with much broader scope and funding. Comparable in technology platforms (genomics, single-cell) and translational ambition, though significantly larger and more diversified than INEM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/NeckerInem
• LinkedInlinkedin.com/company/inem-institut-necker-enfants-malades
• Facebookfacebook.com/InstitutNeckerEnfantsMalades

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Necker Enfants Malades